Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Jaganmohan, Anumolu"'
Autor:
Badry Bursulaya, Yun O. Long, Jaganmohan Anumolu, Matthew McNeill, Sangamesh Badiger, Rina Fong, Michael DiDonato, Mari Manuia, Jie Li, Bender Steven Lee, Jose Juarez, Wenshuo Lu, Gerald Lelais, Daniel E. Mason, Thomas H. Marsilje, John Isbell, Kevin Johnson, Shailaja Kasibhatla, Bei Chen, Glen Spraggon, Pierre-Yves Michellys, Todd Groessl, Robert Epple, Yong Jia, Perry Gordon, Chun Li
Publikováno v:
Journal of Medicinal Chemistry. 59:6671-6689
Over the past decade, first and second generation EGFR inhibitors have significantly improved outcomes for lung cancer patients with activating mutations in EGFR. However, both resistance through a secondary T790M mutation at the gatekeeper residue a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::26a973c726b34b81320ef338d4a330d6
https://doi.org/10.1021/acs.jmedchem.5b01985
https://doi.org/10.1021/acs.jmedchem.5b01985
Autor:
Gérald, Lelais, Robert, Epple, Thomas H, Marsilje, Yun O, Long, Matthew, McNeill, Bei, Chen, Wenshuo, Lu, Jaganmohan, Anumolu, Sangamesh, Badiger, Badry, Bursulaya, Michael, DiDonato, Rina, Fong, Jose, Juarez, Jie, Li, Mari, Manuia, Daniel E, Mason, Perry, Gordon, Todd, Groessl, Kevin, Johnson, Yong, Jia, Shailaja, Kasibhatla, Chun, Li, John, Isbell, Glen, Spraggon, Steven, Bender, Pierre-Yves, Michellys
Publikováno v:
Journal of medicinal chemistry. 59(14)
Over the past decade, first and second generation EGFR inhibitors have significantly improved outcomes for lung cancer patients with activating mutations in EGFR. However, both resistance through a secondary T790M mutation at the gatekeeper residue a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e6581993755c96201e35fb6c7ecb996e
https://pubmed.ncbi.nlm.nih.gov/27433829
https://pubmed.ncbi.nlm.nih.gov/27433829